Zacks: Brokerages Anticipate Apollo Endosurgery, Inc. (APEN) Will Post Earnings of -$0.33 Per Share

Brokerages predict that Apollo Endosurgery, Inc. (NASDAQ:APEN) will announce earnings of ($0.33) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Apollo Endosurgery’s earnings. The lowest EPS estimate is ($0.37) and the highest is ($0.29). Apollo Endosurgery posted earnings per share of ($35.01) in the same quarter last year, which would indicate a positive year-over-year growth rate of 99.1%. The company is scheduled to report its next quarterly earnings results on Wednesday, March 14th.

On average, analysts expect that Apollo Endosurgery will report full-year earnings of ($1.98) per share for the current year, with EPS estimates ranging from ($2.10) to ($1.85). For the next fiscal year, analysts forecast that the business will report earnings of ($1.18) per share, with EPS estimates ranging from ($1.35) to ($1.01). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Apollo Endosurgery.

A number of analysts recently commented on the company. Northland Securities reaffirmed a “buy” rating and issued a $12.00 price target on shares of Apollo Endosurgery in a research note on Tuesday, November 28th. Zacks Investment Research raised Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $9.44.

In other news, VP Bret Schwartzhoff acquired 9,500 shares of the stock in a transaction on Tuesday, November 7th. The stock was acquired at an average price of $4.24 per share, with a total value of $40,280.00. Following the completion of the transaction, the vice president now owns 15,631 shares of the company’s stock, valued at approximately $66,275.44. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 74.20% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. purchased a new position in Apollo Endosurgery during the third quarter valued at $119,000. Woodmont Investment Counsel LLC bought a new position in shares of Apollo Endosurgery during the third quarter valued at $220,000. Russell Investments Group Ltd. bought a new position in shares of Apollo Endosurgery during the third quarter valued at $1,288,000. King Luther Capital Management Corp bought a new position in shares of Apollo Endosurgery during the third quarter valued at $2,567,000. Finally, Stonepine Capital Management LLC bought a new position in shares of Apollo Endosurgery during the third quarter valued at $11,067,000. 23.67% of the stock is owned by institutional investors and hedge funds.

Shares of Apollo Endosurgery (APEN) traded up $0.13 during mid-day trading on Friday, reaching $4.50. Apollo Endosurgery has a fifty-two week low of $3.55 and a fifty-two week high of $21.88. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.54 and a quick ratio of 2.00.

WARNING: “Zacks: Brokerages Anticipate Apollo Endosurgery, Inc. (APEN) Will Post Earnings of -$0.33 Per Share” was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.truebluetribune.com/2018/01/02/zacks-brokerages-anticipate-apollo-endosurgery-inc-apen-will-post-earnings-of-0-33-per-share.html.

About Apollo Endosurgery

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Get a free copy of the Zacks research report on Apollo Endosurgery (APEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply